[go: up one dir, main page]

FR12C0008I1 - - Google Patents

Info

Publication number
FR12C0008I1
FR12C0008I1 FR12C0008C FR12C0008I1 FR 12C0008 I1 FR12C0008 I1 FR 12C0008I1 FR 12C0008 C FR12C0008 C FR 12C0008C FR 12C0008 I1 FR12C0008 I1 FR 12C0008I1
Authority
FR
France
Prior art keywords
transthyretin
misfolding
diseases
treatment
effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32685364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR12C0008(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR12C0008I1 publication Critical patent/FR12C0008I1/fr
Application granted granted Critical
Publication of FR12C0008I2 publication Critical patent/FR12C0008I2/en
Active legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods, screening methods, as well as specific transthyretin stabilizing compounds are disclosed.
FR12C0008C 2002-12-19 2012-02-22 COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING MISFOLDING OF TRANSTHYRETIN Active FR12C0008I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43507902P 2002-12-19 2002-12-19
US46543503P 2003-04-24 2003-04-24
PCT/US2003/040567 WO2004056315A2 (en) 2002-12-19 2003-12-19 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Publications (2)

Publication Number Publication Date
FR12C0008I1 true FR12C0008I1 (en) 2012-03-30
FR12C0008I2 FR12C0008I2 (en) 2013-01-11

Family

ID=32685364

Family Applications (1)

Application Number Title Priority Date Filing Date
FR12C0008C Active FR12C0008I2 (en) 2002-12-19 2012-02-22 COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING MISFOLDING OF TRANSTHYRETIN

Country Status (20)

Country Link
US (6) US7214695B2 (en)
EP (3) EP1988397B8 (en)
JP (3) JP4665076B2 (en)
KR (1) KR101089904B1 (en)
CN (2) CN100448852C (en)
AT (2) ATE524741T1 (en)
AU (2) AU2003303196C1 (en)
BE (1) BE2012C008I2 (en)
BR (1) BRPI0317463B8 (en)
CA (2) CA2510455C (en)
CY (2) CY1108467T1 (en)
DE (2) DE60323155D1 (en)
DK (2) DK1587821T6 (en)
ES (3) ES2524803T3 (en)
FI (1) FI1587821T6 (en)
FR (1) FR12C0008I2 (en)
LU (1) LU91935I2 (en)
PT (2) PT1988397E (en)
SI (1) SI1587821T2 (en)
WO (1) WO2004056315A2 (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06105459B2 (en) * 1988-08-11 1994-12-21 日本電気株式会社 Vector processor
PT1988397E (en) * 2002-12-19 2011-12-02 Scripps Research Inst COMPOSITIONS AND UTILIZATIONS FOR TRANSTYRETIN STABILIZATION AND WIND INHIBITION
PT1740154E (en) * 2004-03-12 2009-09-11 Biodel Inc Insulin compositions with improved absorption
MXPA06013381A (en) 2004-05-20 2007-03-01 Scripps Research Inst Transthyretin stabilization.
WO2006021451A2 (en) * 2004-08-26 2006-03-02 Biostratum Ab Methods and compounds for treating diabetes
JP2009504682A (en) * 2005-08-11 2009-02-05 ザ スクリプス リサーチ インスティテュート Inhibition of transthyretin amyloidosis by genistein
WO2008034016A2 (en) * 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
WO2010054127A1 (en) * 2008-11-05 2010-05-14 Elan Pharmaceuticals, Inc. Methods and agents for stabilizing non-pathological amyloidogenic polypeptides
JOP20190231A1 (en) 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
US20120101021A1 (en) 2009-02-06 2012-04-26 Surendra Sharma Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
WO2011131661A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
US8877795B2 (en) 2010-05-07 2014-11-04 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
RU2586330C2 (en) * 2011-09-16 2016-06-10 Пфайзер Инк. Solid forms of transthyretin dissociation inhibitor
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
CN104350041A (en) 2012-05-07 2015-02-11 塞利克斯比奥私人有限公司 Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168014A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
AU2013264894B2 (en) 2012-05-23 2015-11-19 Cellix Bio Private Limited Compositions and methods for treatment of inflammatory bowel disease
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
WO2014124334A2 (en) 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
PL3977993T3 (en) * 2014-09-08 2024-05-06 Pfizer Inc. Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (en) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ Compositions and methods for the treatment of multiple sclerosis
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN107428697A (en) 2015-01-06 2017-12-01 塞尔利克斯生物私人有限公司 Compositions and methods for treating inflammation and pain
CN107344927A (en) 2016-05-05 2017-11-14 苏州晶云药物科技有限公司 Crystal formation E of Tafamidis meglumine salts and its production and use
CN106496014A (en) * 2016-10-17 2017-03-15 河北美星化工有限公司 A kind of preparation method of diflunisal
US11858974B2 (en) 2017-05-22 2024-01-02 Resq Biotech Macrocyclic modulators of disease associated protein misfolding and aggregation
GB2571950A (en) * 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
CN108558599B (en) * 2018-03-29 2021-01-29 浦拉司科技（上海）有限责任公司 Synthesis process of 2-biphenylyl methanol
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
PL3953339T3 (en) 2019-04-11 2025-05-05 Inke, S.A. Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate
EP4512399A3 (en) 2019-05-16 2025-09-03 Teva Pharmaceuticals International GmbH Solid state forms of tafamidis and salts thereof
CN110215740B (en) * 2019-07-15 2021-05-04 大连医科大学 A kind of preparation method of zwitterion hydrophilic pretreatment silica gel material
WO2021019448A1 (en) * 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
JP2023503833A (en) 2019-11-15 2023-02-01 ▲蘇▼州科睿思制▲葯▼有限公司 Crystalline form of tafamidis, its preparation method and its use
MX2022007787A (en) * 2019-12-20 2022-07-19 Pfizer Ireland Pharmaceuticals Efficient process for making 6-carboxy benzoxazole derivatives.
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
BR112022014635A2 (en) 2020-01-28 2022-10-11 Protego Biopharma Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRRETIN MALFOLDING
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN112683844A (en) * 2020-12-07 2021-04-20 东华理工大学 Research method for influence of vibration on indomethacin-saccharin eutectic formation
CN112858690B (en) * 2021-01-21 2023-11-10 宁波职业技术学院 A kind of urine albumin/urinary creatinine composite quality control product and preparation method thereof
CN114907283B (en) * 2021-02-07 2025-01-28 南京正大天晴制药有限公司 A preparation method of 2-(3,5-dichlorophenyl)-benzoxazole-6-carboxylic acid
EP4083027A1 (en) 2021-04-26 2022-11-02 Química Sintética, S.A. A solid state form of tafamidis and a process for its preparation
CN113372290A (en) * 2021-05-21 2021-09-10 遵义医科大学 Synthetic method of drug Tafamidis
CN113321627B (en) * 2021-06-06 2022-05-24 湖南第一师范学院 A kind of Tafamidis derivative and synthetic method thereof
JP2024523000A (en) 2021-06-08 2024-06-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド Compositions and methods for treating or preventing Stargardt's disease and/or retinal binding protein 4 (RBP4)-associated disorders
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
US20250042864A1 (en) 2021-11-17 2025-02-06 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis
CN114970600B (en) * 2022-04-11 2024-07-26 昆明理工大学 Rolling bearing fault diagnosis method and device based on granulated scattered entropy and optimized KELM
EP4559903A1 (en) 2022-07-22 2025-05-28 Shiratori Pharmaceutical Co., Ltd. Production method for tafamidis or salt thereof
KR20250036933A (en) 2022-07-28 2025-03-14 화이자 인코포레이티드 Tafamidis pharmaceutical composition
US11970468B1 (en) 2023-10-23 2024-04-30 King Faisal University 2-(benzo[d]oxazol-2-yl)-N′-(3,5-dichlorobenzoyloxy)acetimidamide as an antimicrobial compound

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US435079A (en) 1890-08-26 Lock-nut for axles
DE602336C (en) 1933-03-09 1934-09-06 I G Farbenindustrie Akt Ges Process for the production of Kuepen dyes of the anthraquinone series
US3551433A (en) * 1967-06-21 1970-12-29 Us Army Preparation of 4-phenyl-4-acyloxypiperidine
US3551443A (en) * 1968-10-30 1970-12-29 Ciba Ltd 2-phenylbenzoxazole derivatives
USRE29608E (en) * 1972-05-18 1978-04-11 Lilly Industries Limited Benzoxazole derivatives
DE2314238A1 (en) 1973-03-22 1974-09-26 Henkel & Cie Gmbh Anti-inflammatory 2-(tetrazol-5'-yl)-benzoxazoles - prepd. from 2-cyano-benzoazoles and used in cosmetics
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US4025636A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles
DE2619547A1 (en) * 1976-05-04 1977-11-24 Dynamit Nobel Ag PROCESS FOR THE PREPARATION OF 2-ARYL-BENZOXAZOLEN AND 2-ARYL-BENZTHIAZOLEN
US4416892A (en) * 1981-04-23 1983-11-22 Lilly Industries Limited Method of treating hypersensitivity disease with benzoxazole derivatives
US5254692A (en) * 1990-04-06 1993-10-19 Bayer Aktiengesellschaft 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines
DE4011106A1 (en) * 1990-04-06 1991-10-10 Bayer Ag NEW HETEROCYCLIC SUBSTITUTED DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
CA2051518A1 (en) 1990-10-01 1992-04-02 Robert J. Perry Synthesis of heterocyclic compounds
JP3021028B2 (en) 1990-11-19 2000-03-15 株式会社日本化学工業所 Azole type cationic dye
CH681806A5 (en) 1991-03-19 1993-05-28 Ciba Geigy Ag
JPH0517458A (en) 1991-07-04 1993-01-26 Idemitsu Kosan Co Ltd Aromatic compound and method for producing the same
US5354759A (en) * 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0673050A (en) 1992-08-26 1994-03-15 Asahi Glass Co Ltd Heterocyclic compound
JPH0673051A (en) 1992-08-26 1994-03-15 Asahi Glass Co Ltd Benzazole derivative
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
JPH06239849A (en) 1993-02-16 1994-08-30 Canon Inc Optically active compound, liquid crystal composition containing the same, liquid crystal element having the same, display method and display device using the same
DE4304650A1 (en) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Condensed 5-membered heterocycles, processes for their preparation and pharmaceutical compositions containing them
JP3243887B2 (en) 1993-05-28 2002-01-07 三菱化学株式会社 Organic electroluminescent device
JPH0797379A (en) 1993-09-06 1995-04-11 Canon Inc Liquid crystal compound, liquid crystal composition containing the same, liquid crystal element having the same, display method and display device using the same
US5441946A (en) * 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
US5837390A (en) * 1995-05-10 1998-11-17 Sony Corporation Metal complex, method for producing the same and optical device
JP3861930B2 (en) 1995-12-15 2006-12-27 ソニー株式会社 Metal binuclear complex, method for producing the same, and optical element
JPH09227576A (en) 1996-02-23 1997-09-02 Sony Corp Metal dinuclear complex, method for producing the same, and optical element
JP3760508B2 (en) 1996-06-10 2006-03-29 東洋インキ製造株式会社 Organic electroluminescence device material and organic electroluminescence device using the same
WO1997047319A1 (en) 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
FR2767527B1 (en) * 1997-08-25 1999-11-12 Pf Medicament INDOLIC PIPERAZINE DERIVATIVES USEFUL AS MEDICAMENTS AND PREPARATION METHOD
GB9725782D0 (en) * 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
EP1053237B1 (en) 1998-02-04 2003-07-02 The Board Of Regents, The University Of Texas System Inhibition of human telomerase by a g-quadruplex-interaction compound
US6107491A (en) * 1998-07-20 2000-08-22 Ciba Specialty Chemicals Corporation Polymerizable diketopyrrolopyrroles
GB9816654D0 (en) * 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
JP2000100569A (en) 1998-09-22 2000-04-07 Toray Ind Inc Luminescent element
JP2001055332A (en) 1999-06-07 2001-02-27 Saitama Daiichi Seiyaku Kk Iontophresis preparation containing aromatic amidine derivatives
WO2000078733A1 (en) 1999-06-18 2000-12-28 Bayer Aktiengesellschaft Phenoxy fluoropyrimidines
JP2001064166A (en) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd Cataplasm
JP2001064205A (en) 1999-06-25 2001-03-13 Dai Ichi Seiyaku Co Ltd Medication composition
WO2001012183A1 (en) * 1999-08-16 2001-02-22 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
GB9919673D0 (en) 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
JP2001226358A (en) 1999-10-12 2001-08-21 Japan Tobacco Inc Lpl potentiator
JP2001242165A (en) 2000-02-25 2001-09-07 Dai Ichi Seiyaku Co Ltd Reagent for collecting blood
NZ521028A (en) 2000-03-16 2004-07-30 F Carboxylic acid derivatives as IP antagonists
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
JP3945123B2 (en) 2000-04-10 2007-07-18 三菱化学株式会社 Organic electroluminescence device
JP2001301329A (en) 2000-04-20 2001-10-31 Mitsubishi Chemicals Corp Optical recording medium
JP2002003368A (en) 2000-06-23 2002-01-09 Saitama Daiichi Seiyaku Kk Pharmaceutical preparation for percutaneous absorption or absorption through mucous membrane
CA2419420C (en) 2000-08-24 2011-08-02 William E. Klunk Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
JP3786203B2 (en) 2000-11-04 2006-06-14 アベンティス・フアーマ・リミテッド Substituted alkanoic acid
US20070004713A1 (en) 2000-12-07 2007-01-04 Bernard Barlaam Therapeutic benimidazole compounds
EP1345914A1 (en) 2000-12-22 2003-09-24 AstraZeneca AB Therapeutic compounds
GB0118357D0 (en) 2001-07-27 2001-09-19 Syngenta Ltd Chemical compounds
WO2003020698A2 (en) 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US6602619B2 (en) * 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
CN100338040C (en) * 2001-11-16 2007-09-19 日本化学医药株式会社 Xanthine Oxidase Inhibiting Compounds
US20060106074A1 (en) 2001-11-28 2006-05-18 Peter Bernstein Er-b-selective ligands
UA83620C2 (en) * 2001-12-05 2008-08-11 Уайт Substituted benzoxazoles and analogues as estrogenic agents
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
CA2470931A1 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
BR0308537A (en) 2002-03-20 2005-02-09 Metabolex Inc Compound, composition, and methods for treating type 2 diabetes and hyperuricemia, modulating insulin resistance and alleviating hyperlipidemia in an individual and prodrug agent
UA79755C2 (en) 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0226822D0 (en) 2002-11-16 2002-12-24 Oxford Glycosciences Uk Ltd Novel compounds
PT1988397E (en) 2002-12-19 2011-12-02 Scripps Research Inst COMPOSITIONS AND UTILIZATIONS FOR TRANSTYRETIN STABILIZATION AND WIND INHIBITION
CA2512704A1 (en) 2003-01-14 2004-08-05 Merck & Co., Inc. Geminally di-substituted nsaid derivatives as abeta 42 lowering agents
JP2004250411A (en) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk DIAGNOSTIC PROBE FOR AMYLOID beta-ACCUMULATIVE DISEASE AND THERAPEUTIC COMPOUND
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
CN101468965A (en) 2003-03-24 2009-07-01 默克公司 Biaryl substituted 6-membered heterocyles as sodium channel blockers
JP2004302049A (en) 2003-03-31 2004-10-28 Hodogaya Chem Co Ltd Photosensitive resin composition
WO2004092140A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
CN1805945A (en) 2003-04-18 2006-07-19 麦克公司 Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA06013381A (en) * 2004-05-20 2007-03-01 Scripps Research Inst Transthyretin stabilization.

Also Published As

Publication number Publication date
BR0317463A (en) 2005-11-16
AU2010201263A1 (en) 2010-04-22
US20140134753A1 (en) 2014-05-15
ES2373639T3 (en) 2012-02-07
WO2004056315A2 (en) 2004-07-08
EP1988397B1 (en) 2011-09-14
FI1587821T9 (en) 2025-07-30
US20040152140A1 (en) 2004-08-05
EP1988397B8 (en) 2012-02-15
US20060057644A1 (en) 2006-03-16
WO2004056315A8 (en) 2005-12-08
AU2003303196C1 (en) 2021-03-25
FI1587821T6 (en) 2025-06-17
AU2010201263B8 (en) 2013-04-18
ES2524803T3 (en) 2014-12-12
JP2006511612A (en) 2006-04-06
BRPI0317463B8 (en) 2021-05-25
DE60323155D1 (en) 2008-10-02
EP1988397A1 (en) 2008-11-05
CA2510455C (en) 2013-03-12
EP1587821A2 (en) 2005-10-26
PT1988397E (en) 2011-12-02
KR20050090410A (en) 2005-09-13
JP2013256521A (en) 2013-12-26
US7214695B2 (en) 2007-05-08
EP2325651A3 (en) 2011-09-21
BE2012C008I2 (en) 2023-03-07
DK1988397T3 (en) 2011-12-12
EP1587821B3 (en) 2025-04-30
AU2003303196B2 (en) 2010-03-25
SI1587821T1 (en) 2009-02-28
EP2325651A2 (en) 2011-05-25
US7214696B2 (en) 2007-05-08
EP1587821B9 (en) 2025-07-02
US7560488B2 (en) 2009-07-14
SI1587821T2 (en) 2025-06-30
US20120065237A1 (en) 2012-03-15
CY2012005I2 (en) 2015-10-07
EP2325651B1 (en) 2014-10-08
DK1587821T3 (en) 2008-11-10
CN101413143A (en) 2009-04-22
ATE524741T1 (en) 2011-09-15
PT1587821E (en) 2008-09-23
AU2010201263B2 (en) 2012-12-20
LU91935I2 (en) 2012-03-26
US8168663B2 (en) 2012-05-01
CY2012005I1 (en) 2015-10-07
CY1108467T1 (en) 2014-04-09
LU91935I9 (en) 2019-01-04
DE122012000007I1 (en) 2012-04-12
KR101089904B1 (en) 2011-12-05
FR12C0008I2 (en) 2013-01-11
DK1587821T6 (en) 2025-05-26
WO2004056315A3 (en) 2005-08-11
CA2800237C (en) 2016-05-17
AU2003303196A1 (en) 2004-07-14
ATE405840T1 (en) 2008-09-15
JP4665076B2 (en) 2011-04-06
ES2312857T3 (en) 2009-03-01
CN1747965A (en) 2006-03-15
CA2510455A1 (en) 2004-07-08
JP2010270134A (en) 2010-12-02
JP5756151B2 (en) 2015-07-29
US20070078186A1 (en) 2007-04-05
CA2800237A1 (en) 2004-07-08
US20100120919A1 (en) 2010-05-13
AU2010201263A8 (en) 2013-04-18
EP1587821A4 (en) 2007-05-09
US8653119B2 (en) 2014-02-18
BRPI0317463B1 (en) 2017-04-18
CN100448852C (en) 2009-01-07
ES2312857T7 (en) 2025-06-13
CN101413143B (en) 2013-09-18
EP1587821B1 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
FR12C0008I1 (en)
MXPA05012323A (en) Cyclic sulfonamides for inhibition of gamma-secretase.
EA200600240A1 (en) CONDENSED ARYL AND HETEROYARIL DERIVATIVES AS METABOLISM MODULATORS AND FOR PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH MATERIAL DISORDERS
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
IL174210A0 (en) 1,4 disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
GB0318447D0 (en) Therapeutic agents
GB0206711D0 (en) HIF Inhibitor
EA200601555A1 (en) Substituted indazole-glucosides
UA86599C2 (en) Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
MXPA02007099A (en) Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging.
EA200600078A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DISEASES
GB0223038D0 (en) Therapeutic compounds
EA200501348A1 (en) SUBSTITUTED ARYL AND HETEROYARILE DERIVATIVES USED AS MODULATORS OF GLUTE METABOLISM METABOLISM AND FOR PREVENTION AND TREATMENT OF RELATED DISORDERS
MXPA05012680A (en) Novel substituted 3-sulfur indoles.
MXPA05013251A (en) Compositions for improved oxidative status in companion animals.
MXPA05004121A (en) Methods of treating dry eye disease with lantibiotics.
DE50306066D1 (en) FUNGICIDAL MIXTURES FOR COMBATING REISPATHOGENESE
BR0214923A (en) Arrangement and method for treating a pumping substance
BR0214244A (en) Use of an ascomycin
DE60215947D1 (en) PYRIDINE-2-YL-METHYLAMINE DERIVATIVES FOR THE TREATMENT OF OPIATIVE VEGETABLES
TW200505836A (en) Cyclic sulfonamides for inhibition of gamma-secretase
PT1551850E (en) 2 OXO-VORUSCHARINA AND ITS DERIVATIVES
WO2004071433A3 (en) Methods of treating disease
MY135225A (en) Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders